Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: A case-control series

HPB

Volumn 15, Issue 1, 2013, Pages 71-77

  Jones, Robert P ^a,b   Dunne, Declan ^a,b   Sutton, Paul ^a,b   Malik, Hassan Z ^b   Fenwick, Stephen W ^b   Terlizzo, Monica ^b   O'Grady, Elizabeth ^b   Koelblinger, Claus ^c   Stättner, Stefan ^b   Stremitzer, Stefan ^c   Gruenberger, Thomas ^c   Poston, Graeme J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ADULT; AGED; ANGIOGRAPHY; ARTIFICIAL EMBOLISM; CASE CONTROL STUDY; CASE REPORT; CLINICAL EFFECTIVENESS; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; FIBROSIS; HEPATIC ARTERY; HOSPITAL DISCHARGE; HUMAN; LAPAROTOMY; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84870930179     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00587.x     Document Type: Conference Paper

References (34)

1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al,. (2002) Trends in longterm survival following liver resection for hepatic colorectal metastases. Ann Surg 235: 759-766.
2. Nordlinger B, Vaillant JC, Guiguet M, Balladur P, Paris F, Bachellier P, et al,. (1994) Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12: 1491-1496.
3. Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H,. (2001) Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 25: 1129-1133.
4. Crowe PJ, Yang JL, Berney CR, Erskine C, Ham JM, Fisher R, et al,. (2001) Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 25: 996-1001.
5. Mala T, BÃhler G, Mathisen BA, SÃreide O,. (2002) Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 26: 1348-1353.
6. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E,. (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88: 980-985.
7. Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, et al,. (1999) Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum 42: 632-639.
8. Wang JY, Chiang JM, Jeng LB, Changchien CR, Chen JS, Hsu KC,. (1996) Resection of liver metastases from colorectal cancer: are there any truly significant clinical prognosticators? Dis Colon Rectum 39: 847-851.
9. Rees M, Plant G, Bygrave S,. (1997) Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 84: 1136-1140.
10. Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C,. (1996) Patient selection for hepatic resection of colorectal metastases. Arch Surg 131: 322-329.
11. Schlag P, Hohenberger P, Herfarth C,. (1990) Resection of liver metastases in colorectal cancer-competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 16: 360-365.
12. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP,. (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110: 13-29.
13. Bakalakos EA, Burak WE, Young DC, Matin EW,. (1999) Is carcinoembryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg 177: 2-6.
14. Folprecht G, Grothey A, Alberts S, Raab H-R, Köhne C-H,. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319.
15. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al,. (2001) Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal. Ann Surg Oncol 8: 347-353.
16. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al,. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237.
17. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al,. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676.
18. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al,. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomized controlled trial. Lancet 371: 1007-1016.
19. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al,. (2012) EORTC liver metastases intergroup randomized Phase III study 40983: longterm survival results. J Clin Oncol 30. Abstract 3508.
20. Van Cutsem E, Nordlinger B, Adam R, Köhne C-H, Pozzo C, Poston G, et al,. (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42: 2212-2221.
21. Kemeny NE, Melendez FDH, Capanu M, Paty PB, Fong Y, Schwartz LH, et al,. (2009) Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27: 3465-3471.
22. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, et al,. (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201: 57-65.
23. Jones R, Fenwick S, Malik H, O'Grady E, Terlizzo M, Gruenberger T, et al,. (2012) Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug-eluting beads transarterial chemoembolization (DEBIRI-TACE): a multi-institute Phase II study in resectable metastases. J Clin Oncol 30. Abstract 3613.
24. Takahashi M, Hasegawa K, Arita J, Hata S, Aoki T, Sakamoto Y, et al,. (2012) Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. Br J Surg 99: 1271-1277.
25. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al,. (2007) Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299-304.
26. Martin RCG, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, et al,. (2010) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18: 192-198.
27. Martin RCG, Scoggins CR, Tomalty D, Schreeder M, Metzger T, Tatum C, et al,. (2012) Irinotecan drug-eluting beads in the treatment of chemo-naïve unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and Phase I trial. J Gastrointest Surg 16: 1531-1538.
28. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al,. (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a Phase III study. Anticancer Res 32: 1387-1395.
29. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al,. (2008) Pathologic response to preoperative chemotherapy: a new outcome endpoint after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344-5351.
30. Poultsides GA, Bao F, Servais EL, Hernandez-Boussard T, Dematteo RP, Allen PJ, et al,. (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19: 2797-2804.
31. Jones RP, Jackson R, Dunne DFJ, Malik HZ, Fenwick SW, Poston GJ, et al,. (2012) Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 99: 477-486.
32. Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P,. (2004) Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 11: 500-505.
33. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al,. (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945.
34. Tan MCB, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM,. (2007) Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11: 1112-1119.